Physician profile
Gregory William Niemer
NPI 1356449367
$2,868,309.40
in general payments reported to CMS, 2019-2025
41 companies · $1.3M in 2025
The $1.3M reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $101K · 2021: $208K · 2022: $459K · 2023: $629K · 2024: $126K · 2025: $1.3M.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $1.3M · Royalty Or License: $624K · Consulting Fee: $116K · Grant: $21K · Food and Beverage: $10K · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $1,275,000.00 |
| Royalty Or License | $624,221.41 |
| Consulting Fee | $116,071.43 |
| Grant | $20,959.00 |
| Food and Beverage | $10,057.40 |
| Education | $264.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| American Rheumatology Network, LLC | $2,792,409.67 | 2019-2025 | |
| Abbvie INC. | $38,589.70 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $10,785.63 | 2019-2020 | |
| Glaxosmithkline, LLC. | $8,254.52 | 2019-2025 | Benlysta |
| Pfizer INC. | $3,067.43 | 2019-2025 | |
| Janssen Biotech, INC. | $2,794.21 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $2,479.09 | 2019-2025 | Krystexxa, Tavneos, Enbrel |
| Novartis Pharmaceuticals Corporation | $1,349.94 | 2019-2025 | |
| Ucb, INC. | $1,253.22 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals Lp | $1,190.28 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $1,037.05 | 2019-2025 | Taltz, Zepbound |
| Octapharma USA, INC. | $1,019.66 | 2022-2025 | Octagam Immune Globulin (Human) |
| E.R. Squibb & Sons, L.L.C. | $788.34 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $389.52 | 2019-2023 | Krystexxa |
| Organon LLC | $385.01 | 2021-2025 | Hadlima, Renflexis |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$8,773,674.69 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Niemer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.